item management s discussion and analysis of financial condition and results of operations 
the following discussion and analysis of our financial condition and results of operations should be read together with selected financial data and our audited consolidated financial statements and related notes appearing elsewhere in this report 
any discussion and analysis regarding our future financial condition and results of operations are forward looking statements that involve risks  uncertainties and assumptions  as more fully identified in forward looking statements and risk factors 
our actual future financial condition and results of operations may differ materially from those anticipated in the forward looking statements 
overview surmodics is a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry 
in fiscal our business performance continued to be driven by growth in our medical device hydrophilic coatings royalty revenue 
our drug delivery royalty and product revenue declined because of cor 
table of contents dis s termination of its exclusivity arrangements under one of its license agreements 
the medical device segment overcame this license termination by increasing new license agreements and continued activities with other medical device customers 
our in vitro diagnostics segment delivered solid revenue growth from existing products  new product launches and the addition of new diagnostic test kit manufacturer customers 
as further discussed in item overview sale of pharmaceuticals business  in december we announced that the board of directors of the company authorized the company to explore strategic alternatives for our pharmaceuticals business  including a potential sale of that business 
this decision by the board reflected our focus on returning the company to profitable growth  and our renewed commitment to pursuing growth opportunities and investments in our medical device and in vitro diagnostics businesses 
on november   we entered into a purchase agreement to sell substantially all of the assets of surmodics pharmaceuticals to evonik 
under the terms of the purchase agreement  the entire portfolio of products and services of surmodics pharmaceuticals  including its cgmp development and manufacturing facility located in birmingham  alabama  were sold 
the company retained all accounts receivable and the majority of liabilities associated with the surmodics pharmaceuticals business incurred prior to closing 
the pharma sale closed on november  the total consideration received from the pharma sale was million in cash 
we have reported the pharmaceuticals segment as discontinued operations beginning in the first quarter of fiscal  as disclosed in notes and to the consolidated financial statements in 
